GlassScriptPhysician profile
Donovan David Runyan
NPI 1699752774
$10,896.64
in general payments reported to CMS, 2019-2025
52 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,839 · 2020: $2,219 · 2021: $2,123 · 2022: $1,825 · 2023: $1,870 · 2024: $20.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,890.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,414.55 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,120.69 | 2019-2023 | Rybelsus, Ozempic |
| Abbvie INC. | $997.44 | 2019-2023 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $949.44 | 2019-2023 | Farxiga, Breztri |
| Lilly USA, LLC | $842.34 | 2019-2023 | Jardiance, Mounjaro, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $768.16 | 2019-2023 | Synjardy, Jardiance |
| Sanofi-Aventis U.S. LLC | $607.39 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $478.99 | 2019-2023 | Trintellix |
| Gilead Sciences, INC. | $422.85 | 2019-2023 | |
| Allergan, INC. | $313.60 | 2019-2020 | |
| Pfizer INC. | $264.71 | 2019-2023 | |
| Abbott Laboratories | $214.64 | 2019-2024 | Proclaim, Mitraclip, Freestyle Libre 2 |
| Kowa Pharmaceuticals America, INC. | $183.35 | 2019-2022 | |
| Amgen INC. | $174.73 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $172.12 | 2019-2023 | Xifaxan |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donovan Runyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.